Circulating vascular endothelial growth factor is not increased ment of the presenting episode, the majority of children during relapses of steroid-sensitive nephrotic syndrome.
in the disease pathogenesis [1] , the precise etiology is, as endothelial cell mitogen and enhancer of vascular permeability.
yet, undetermined, and histologic examination of renal Results. Plasma VEGF levels and urine VEGF/creatinine patients with SSNS. PBMC supernatant from SSNS paratios were not elevated in SSNS relapse compared with remistients in relapse, when injected into guinea pig skin in sion and control samples. Peripheral blood mononuclear cell the Miles assay [2] produced an increase in local capillary VEGF mRNA expression was no different in SSNS patients permeability that was not observed upon injection with compared with controls. The administration of VEGF to rats induced an acute reversible fall in systemic blood pressure supernatant from SSNS patients in remission and normal but did not result in the development of either proteinuria or controls [3, 4] , CD4ϩ lymphocytes being later shown to glomerular histologic change.
be the predominant source of this factor [5] . Infusion of into the rat renal artery has been shown to produce
Further studies are warranted to investigate intrarenal VEGF expression.
a reduction in colloidal iron staining of the basement membrane, indicative of loss of anionic charge and foot process fusion [6] , and also to increase urinary protein Childhood steroid-sensitive nephrotic syndrome excretion in the first 12-hours postinfusion [7] . T-cell (SSNS) is characterized by the abrupt onset of proteinhybridomas from peripheral blood T cells isolated from uria, which, if untreated, rapidly results in the develop-SSNS patients in relapse have also been shown to induce ment of generalized edema. Following successful treatproteinuria in the rat [8] . In a further model, Bakker et al cultured isolated Con A-stimulated monocytes from patients with SSNS and other proteinuric glomerulopathies ity factor, although no purified cloned product emerged were to determine whether (a) circulating (plasma) or urinary VEGF levels were increased in children during from these studies. Furthermore, similar findings in the Miles assay using PBMC supernatants from patients with relapses of SSNS compared with levels in children in remission and healthy age-and sex-matched controls, other nephropathies, including IgA nephropathy [10], suggest that this uncharacterized factor is not unique to SSNS (b) PBMC VEGF mRNA expression was different in children with SSNS compared with healthy controls, and and may be circulating in any proteinuric nephropathy.
Vascular endothelial growth factor (VEGF), also (c) the administration of rVEGF resulted in the development of proteinuria in the Sprague-Dawley rat. known as vascular permeability factor (VPF), is a disulfide-linked homodimer of 34 to 42 kDa. It is an endothelial cell mitogen [11] that promotes angiogenesis and also METHODS has potent vascular permeability-enhancing properties Vascular endothelial growth factor enzyme-linked im- [12] . Alternate splicing of mRNA results in the generamunosorbent assay kits were purchased from R&D Systion of four protein species of 121, 165, 189, and 206 tems (Abingdon, UK). rVEGF for the animal studies amino acids. On the basis of protein structure, particuwas a kind gift from Dr. D. Ogilvie of Zeneca Pharmalarly the pattern of conserved cysteines and sequence ceuticals (Alderley Edge, UK). Lymphocyte separation homology, VEGF has been considered to be a member medium (Optiprep) was purchased from Robins Scienof the PDGF protein family [13] .
tific (Knowle, UK). Sprague-Dawley rats were purchased Vascular endothelial growth factor mediates biological from Charles Rivers (Margate, UK). Taq DNA polymerfunction by interaction with two specific tyrosine kinase ase, Superscript reverse transcriptase, RNase inhibitor, receptors on endothelial cells: fms-like tyrosine kinase oligo (dT) 12-18 , 100 bp DNA ladder, and dNTP solutions (flt-1) [14] and kinase insert domain containing receptor were all purchased from Life Technologies (Paisley, UK). (KDR) [15] , also known as VEGFR1 and VEGFR2, respectively. In an experimental model, a systemic injecPlasma and urine VEGF levels in childhood SSNS tion of VEGF has been reported to induce proteinuria Plasma and urine samples were collected from children (abstract; Iijima et al, J Am Soc Nephrol 3:514, 1992).
with relapsing SSNS during disease relapse and reTopical application of VEGF to the rat cremaster muscle mission and from age-and sex-matched normal controls. [16] and infusion of VEGF into the parietooccipital corChildren receiving regular immunomodulatory therapy tex of mice [17] have been shown to increase capillary and those who had received corticosteroids within six permeability within 30 minutes. Coincident with these weeks or alkylating agents (cyclophosphamide or chlorlocal changes in capillary endothelium is the dynamic, ambucil) within six months were excluded from the temporal appearance of interendothelial gaps and the study. Ethical approval was granted by the Salford Area formation of fenestrae-like openings.
Health Authority Ethical Committee. Relapse samples Vascular endothelial growth factor is known to be were collected early during disease relapse. Parents were constitutively expressed by a wide range of normal adult asked to contact the department as soon as possible after tissues [18] , including glomerular epithelial cells [19] , the development of proteinuria, allowing samples to be and PBMCs have been reported to both express VEGF collected before the children became clinically nephrotic mRNA [20] and to secrete VEGF protein (abstract; Wat-(as part of routine clinical care, families of children with son et al, J Am Soc Nephrol 7:1725 Nephrol 7: , 1996 . Glomerular SSNS are instructed to test their child's early morning endothelial cells have been shown to express mRNA for urine for proteinuria on a daily basis using Albustix). both VEGF receptors, flt-1 and KDR [19] . Dysregulated Remission samples were collected during periods of sta-VEGF expression has previously been implicated in a ble remission. Control samples were collected from othnumber of pathological situations, including tumor angierwise healthy children undergoing minor elective surgiogenesis/metastasis [21] , rheumatoid arthritis [22, 23] , cal procedures under general anesthesia. Samples were diabetic retinopathy [24, 25] , ovarian hyperstimulation collected within two minutes of induction of anesthesia syndrome [26] , and glomerular disease associated with prior to the commencement of surgery. A separate venimesangial proliferation (abstract; Iijima et al, J Am Soc puncture site was chosen rather than using the intraveNephrol 6:923, 1995).
nous cannula to obtain samples in order to avoid any In view of the seemingly considerable body of evicontamination by intravenous anesthetic agents. Blood dence to support a potential role for VEGF in the pathowas collected into Becton and Dickenson ethylenedigenesis of SSNS, we undertook the following series of aminetetraacetic acid (EDTA) blood tubes (0.072 ml investigations. Our hypothesis was that exposure of glo-7.5% EDTA per 3 ml sample), and centrifugation of merular capillary cells to circulating VEGF or VEGF samples (2000 r.p.m. for 10 min) and separation of produced locally in the kidney would modulate endotheplasma was performed within two hours of venipuncture. lial permeability through a noninflammatory mechanism, thus inducing albuminuria. The specific aims of the study Plasma was used in preference to serum, as we have previously shown that a significant increase in measured cDNA template and competitive fragment DNA for the VEGF and ␤-actin RT-PCR amplifications. RT-PCR of VEGF levels occurs upon clotting of blood due to platelet VEGF release [27] . Early morning urine samples were the samples was carried out in a 20 l reaction overlaid with paraffin oil containing 1/25th volume (4%) of the collected into universal containers. Plasma and urine samples were stored in multiple aliquots at Ϫ80ЊC prior cDNA reaction; 10 pmol of each primer (with the forward primer 5Ј fluorescently end labeled with a CY5 to assaying.
Plasma and urine VEGF levels were measured using tag); 0.75 mm of each dNTP; 10% dimethyl sulfoxide; 3.5 mm MgCl 2 ; 16.6 mm (NH 4 ) 2 SO 4 ; 67 mm Tris-HCl, pH a monoclonal antibody (mAb)-mediated capture ELISA (R&D Systems). Urinary protein levels were measured 8.0; 85 g/ml bovine serum albumin and 0.5 units of Taq DNA polymerase; and either 10 fg of VEGF or 1 pg using a benzethonium chloride-binding assay (Hitachi 911 autoanalyzer), and urinary creatinine levels were of ␤-actin competitive DNA fragment as appropriate. Thermal cycling conditions consisted of an initial denameasured using a kinetic Jaffe method (Hitachi 911 autoanalyzer). Urine VEGF levels were expressed as a turation step at 94ЊC for three minutes followed by 30 cycles for VEGF and 25 cycles for ␤-actin at 94ЊC for VEGF/creatinine ratio to correct for variation in urine concentration between samples. one minute; 55ЊC for one minute and 65ЊC for one minute for VEGF and ␤-actin, respectively; and 72ЊC for one Semiquantitative VEGF mRNA expression in PBMCs minute, with a final extension step at 72ЊC for five minin childhood SSNS utes. VEGF transcript expression was quantitated for each isoform using the ALFexpress DNA analysis sysAt the time of venous sampling for obtaining plasma samples, a further sample of blood was collected from tem (Pharmacia Biotech, Quebec, Canada). One microliter of PCR product was electrophoresed in duplicate children with SSNS in relapse into Becton and Dickenson EDTA tubes for isolation of PBMCs. These were isolated through a 6% 39:1 acrylamide:bis-acrylamide 1 ϫ TBE gel, and average values of peak fluorescence were deterfrom the whole blood samples by the centrifugation of cells through lymphocyte separation medium (Flow Labmined. Transcript values were divided by competitive fragment values to correct for inter-PCR variation and oratories, Irvine, UK). Total RNA was extracted from PBMC cell pellets using a modification of the guanidinwere then expressed as a ratio of the peak area fluorescence of the transcript of interest over the ␤-actin tranium thiocyanate-phenol-chloroform method [28] . cDNA was synthesized from 5 g of total RNA using Superscript. script reverse transcriptase and oligo (dT) [12] [13] [14] [15] [16] [17] [18] according Experiments to determine whether the administration to the manufacturer's instructions. Semiquantitative reof rVEGF induces proteinuria in the verse transcriptase-polymerase chain reaction (RT-PCR) Sprague-Dawley rat was performed using previously described primers known to amplify all reported VEGF splice variants [20] . In addiShort-term follow-up model. All animal care was in accordance with United Kingdom Home Office guidetion, primers designed to amplify ␤-actin [29] were used to control for variation in cDNA template concentration, lines. Ten male Sprague-Dawley rats (mean weight 244.9 g Ϯ sd 27.7 g; Charles Rivers, UK) were anestheand competitive DNA fragments were constructed for both PCR reactions to control for inter-PCR amplificatized by the administration of a bolus of 100 mg/kg of intraperitoneal thiopentone; further intraperitoneal doses tion variation.
A VEGF competitive DNA fragment of 269 bp was of 2 mg/kg were given if necessary until surgical anesthesia was attained. Following shaving of the neck and abdogenerated using the primers: forward 5ЈCGAAGTGGT GAAGTTCATGGATGATAGAGCAAGACAAGA men, animals were placed in the prone position on a heated operating table. The neck vessels were exposed, AAATCCCTG3Ј and reverse, 5ЈTTCTGTATCAGTC TTTCCTGGTGAG3Ј (sequences in bold denote primand following ligation of the vessel distally, the left external jugular vein was cannulated using PP10 tubing (Orme ers used in VEGF cDNA amplification, and the underscored sequence corresponds to nucleotide 460-484 GenScientific, Manchester, UK). A bolus of 1 ml 0.9% saline warmed to 37ЊC was administered over a two-minute Bank accession no. M32977). A ␤-actin competitive DNA fragment of 225 bp was generated using the primers:
period, followed by a continuous infusion of 200 l/min to ensure that a good urine output was maintained. The forward 5ЈGCCGTCTTCCCCTCCATCGAAGTACC CCATCGACGACGG3Ј and reverse 5ЈTAGCAACGT right internal carotid artery was then exposed and, following ligation of the distal vessel, was cannulated using ACATGGCTGGGG3Ј (sequences in bold denote primers used in ␤-actin cDNA amplification, and underlined PP50 tubing and connected via a Statham pressure transducer (P23 Dc) to a Grass Polygraph (model 79C) to sequence corresponds to nucleotide 242-262 GenBank accession no. X00351). Titration experiments were conprovide systemic blood-pressure monitoring. Only animals in which the mean arterial blood pressure (BP) was ducted (data not shown) to determine the optimum number of amplification cycles and the optimum amounts of sustained above 80 mm Hg for the entire duration of the experiment were accepted for inclusion into the study. A Dawley rats (mean weight 238.3 g Ϯ sd 15.1 g; Charles Rivers, London, UK) were placed in metabolic cages tracheotomy was performed using a diathermy loop to ensure a clear airway.
for a two-day period prior to commencement of the experimental period to allow complete acclimatization. A midline laparotomy incision was made, and the left ureter was catheterized using PP10 tubing to allow colThroughout the entire period of experimentation, animals were allowed free access to water and were fed lection of urine from the left kidney. A baseline urine sample from the left kidney was then collected over a standard chow in powdered form to prevent food being dragged from the feed hoppers into the main body of the 30 minute period into a preweighed eppendorf. At this point, 50 g of rVEGF 165 in a total volume of 500 l cage (thus avoiding possible contamination of collected urine with protein-containing feed). Room temperature 0.9% saline or an identical volume of 0.9% saline alone (5 animals in each group) were infused into the animal remained constant, and standard 12-hour light and dark cycles were used. At 0700 hours on experimental day 1, over a 10-minute period via the external jugular vein using a Graseby syringe pump. A dose of 50 g was the metabolic cages were washed thoroughly, and the first 12-hour baseline urine collection commenced. At chosen on the basis of a previous report (abstract; Iijima et al, J Am Soc Nephrol 3:514, 1992), suggesting that this 1900 hours on the same day, using an aseptic technique, animals were administered either 50 g rVEGF 165 in 1 dose induced proteinuria. Human rVEGF 165 has previously been shown to be biologically active in rat models ml 0.9% saline or 1 ml 0.9% saline by slow intravenous injection into a tail vein using a 23G cannula. [16] , and physiological responses relating to altered vascular wall function have been reported to occur rapidly Following the infusion of either VEGF or saline, urine was collected every 12 hours for a total of 72 hours (six in both the Miles assay [2] and a rat cremaster muscle model [16] . The biological activity of the rVEGF 165 used 12-hour samples). Urine was collected into preweighed containers. After repeat weighing to calculate the volhad previously been confirmed in endothelial cell mitogenesis assays (A. Canfield, University of Manchester, ume of urine passed, the urine was microfuged to remove debris and was stored in multiple aliquots at Ϫ80ЊC prior UK, personal communication). Following completion of the 10-minute period of intravenous infusion, a further to assaying. At the end of the 72 hour period of urine collection, the animals were sacrificed, and the left kidfour 15-minute timed collections were made, after which the left kidney was instantly removed and divided into ney was instantly removed and placed in 10% neutralbuffered formalin. Tissues were processed for light mitwo portions. One (for light microscopy studies) was placed in 10% neutral-buffered formalin, and the other croscopy by the Department of Pathological Sciences, University of Manchester, UK. (for electron microscopy studies) was placed in 2.5% glutaraldehyde in cacodylate buffer. Animals were then Urine total protein concentrations were measured as described earlier here. Total protein excretion was exsacrificed by overdosing with intravenous anesthetic. A terminal blood sample was collected into an EDTA pressed as mg per 12-hour period, calculated using the product of the protein concentration and the volume of blood tube for the measurement of plasma VEGF levels using the mAb-mediated capture assay. Tissues were urine passed. processed for light microscopy and electron microscopy Statistical analysis by the Department of Pathological Sciences, University of Manchester, UK. The diameter of endothelial fenesPlasma VEGF levels and urine VEGF/creatinine ratios were shown not to be normally distributed, and trations was measured in electron micrographs (magnification ϫ39,000). Capillary loops were selected ranthe Kruskal-Wallis test was used to compare relapse, remission, and control values. The Mann-Whitney test domly for measurement and with a minimum of 10 glomeruli being examined in each kidney. The mean was used to compare VEGF mRNA levels. Calculations were performed using GraphPad Prism (GraphPad (range) number of fenestrations measured in each kidney was 93 (73 to 114).
Software Inc., USA). Urine volumes were calculated by reweighing the preweighed eppendorfs and subtracting the pre-experimen-RESULTS tal from the post-experimental weights. Urine samples Plasma and urine VEGF levels in childhood SSNS were frozen and batched for measurement of total protein concentration using a colorimetric assay (BioRad, Twenty-two children (16 boys and 6 girls) with SSNS were studied in relapse, and 13 (11 boys, 2 girls) were Hemel Hempstead, UK) for protein concentration based on the Lowry assay [30] . Protein excretion from the left studied in remission. The mean (sem) age of the relapse group was 8.7 (Ϯ1.08) years, and the remission group's kidney was expressed as milligrams per hour, calculated using the product of the protein concentration and the mean age was 9.3 (Ϯ1.40) years. All children in both relapse and remission groups were not on maintenance volume of urine passed.
Longer term follow-up model. Eight male Spragueimmunomodulatory therapy and had not received oral corticosteroids in the preceding six weeks or cyclophosphamide in the preceding six months. Control subjects (N ϭ 24) had a mean age of 7.2 (Ϯ0.94) years. There was no significant difference in the ages or male:female ratios between the three groups. All children had their urinary protein excretion quantitated by measurement of an early morning protein/ creatinine ratio (normal range less than 25 mg/mmol, nephrotic proportion proteinuria more than 250 mg/ mmol). This confirmed the presence of nephrotic proportion proteinuria in the relapse group and the absence of proteinuria in the remission and control groups.
Plasma VEGF levels were not significantly increased in children with SSNS in relapse (N ϭ 22, median 50.6 pg/ml, interquartile range 31.2 to 97.3 pg/ml) compared with remission (N ϭ 13, 31.2 pg/ml, 31.2 to 39.1 pg/ml) or normal age-and sex-matched controls (N ϭ 24, 61.1 pg/ml, 31.2 to 104.3 pg/ml; P ϭ 0.295 Kruskal-Wallis test; Fig. 1A ). Urine VEGF/creatinine ratios ( 
VEGF mRNA expression in PBMCs in childhood SSNS
Nine children with SSNS in relapse and nine normal control children were studied. Semiquantitative RT-PCR studies of VEGF mRNA expression in unstimulated PBMCs did not show any significant difference 
Sprague-Dawley rat
Short-term follow-up model. Both VEGF and control groups of animals were of similar weight [VEGF group the relative volume expansion produced by the continumean (Ϯsd) weight 250.2 g (Ϯ16.5 g), control group ous saline infusion (Fig. 2B ). In the VEGF-administered 239.6 g (Ϯ7.7 g), P ϭ NS, unpaired t-test]. There was animals that received an identical volume of 0.9% saline no significant difference between the BPs of the two during the period of experimentation, there was a fall groups of animals in the 30-minute run-in period prior in urine output to below baseline levels for the first 45-to the commencement of the infusion. In animals adminminutes after completion of the VEGF infusion. Urinary istered VEGF, there was an acute and precipitous fall protein excretion similarly fell in the VEGF-treated in systemic BP immediately upon commencement of the group, with excretion remaining constant in the saline VEGF infusion (Fig. 2A) . The mean BP at two-minutes control animals (Fig. 2C) . Terminal plasma VEGF levels after commencement of the VEGF infusion was signifiin control animals were all below the background deteccantly lower than baseline (t0) values (P ϭ 0.003, paired tion limit of the mAb-mediated capture assay, whereas t-test). This fall in BP was transient, with recovery to in VEGF-treated animals, despite 1 in 10 dilution of close to preinfusion levels occurring by 30-minutes postsamples, plasma levels were in gross excess of the upper infusion. No similar effect was seen in the control animals detection limit of the assay, indicating circulating VEGF administered a 1 ml bolus of 0.9% saline. levels to be in excess of 20 ng/ml. Light and electron In the control animals, urine output increased steadily throughout the period of experimentation secondary to microscopy studies on renal tissue submitted from three VEGF-administered and three control animals revealed In addition to failing to detect increased circulating no abnormality in either group. In particular, electron VEGF levels in human subjects with SSNS, it was also microscopy studies showed no evidence of podocyte foot not possible to induce proteinuria in the Sprague-Dawley process abnormality in VEGF-treated animals, and the rat by the administration of recombinant human VEGF diameter of endothelial cell fenestrations was not sigusing both a short-term and a longer term model. The nificantly greater in the VEGF-treated group than the choice of dose of VEGF, mode of administration, and saline control group [median (interquartile range) diamtime courses studied warrant further discussion. As preeter 103 nm (77 to 128 nm) and 120 (85 to 154 nm), viously outlined, a dose of 50 g was chosen because a respectively, P ϭ 0.17, Mann-Whitney test].
previous report suggested that this would induce proteinuria (abstract; Iijima et al, J Am Soc Nephrol 3:514, 1992); Longer term recovery model if proteinuria had occurred, further experiments would Both VEGF-treated and saline control animals were have been performed using lower, more physiological of similar weights [VEGF group mean (Ϯsd) weight VEGF doses. VEGF was administered systemically 235.5 g (Ϯ7.9 g), control group 241.0 g (Ϯ8.1 g), P ϭ rather than directly into the renal artery or descending NS, unpaired t-test]. All animals were inspected on a aorta to avoid any possible renal hypoxia associated with twice-daily basis throughout the entire experimental pevessel cannulation, hypoxia being well recognized as a riod and remained well, with no adverse clinical signs.
potent stimulus for up-regulation of VEGF mRNA exUrine output showed significant diurnal variation in both pression [31] [32] [33] . Widespread binding of administered VEGF and saline control-treated animals, with increased VEGF to receptors on endothelium throughout the enurine production during the overnight 12-hour period tire vasculature as a potential cause of the absence of (1900 to 0700 hr) compared with the daytime periods any observed effect was excluded by the detection of (0700 to 1900 hr) (Fig. 3A) . There was no significant high circulating levels (more than 20 ng/ml) in VEGFdifference in urine output between the two groups. Protreated animals at the end of the experimental period. tein excretion showed similar diurnal variation in both Although we did not formally test whether an even groups (Fig. 3B) . No difference in protein excretion was higher VEGF dose would result in the development of detected between the VEGF-treated and saline control proteinuria, this would appear unlikely in view of this animals.
finding. A 60-minute preliminary follow-up period was Light microscopy studies on renal tissue submitted chosen, as it was anticipated that any VEGF-induced from both VEGF-administered and control animals rechanges might occur within this time frame in view of vealed no abnormality in either group. the rapidity of biological action detected in both the Miles assay [2] and the rat cremaster muscle model [16] . In addition to a complete absence of any evidence of a DISCUSSION VEGF-induced functional change in the form of proteinWe have clearly shown that circulating VEGF levels, uria, there was no histologic change noted at either light as measured using a mAb-mediated capture assay, are or electron microscopy levels, in particular no evidence not elevated during relapses of childhood SSNS comof foot process fusion or alteration in endothelial fenespared with both remission and normal controls. This tration. The rationale for including the transmission elecmAb-mediated capture assay is known to measure both tron microscopy analysis, in particular the quantitation free VEGF 121 and VEGF 165 , and, therefore, it is not possiof the size of glomerular endothelial cell fenestrae, was ble to determine which is the predominant protein varithat VEGF binding to endothelium, both in vivo [16, ant being measured, although we have previously shown 17] and in vitro [34] , clearly modulates the number and that this assay detects only free VEGF and not VEGFstructure of fenestrae as part of the mechanism controlflt-1 complexes [27]. Semiquantitative RT-PCR studies ling capillary permeability. If structural change in the showed no difference in PBMC VEGF mRNA expression between SSNS relapse and control groups. endothelium had occurred in the kidney subsequent to VEGF administration, this may not have automatically led to functional proteinuria through compensatory mechanisms operating at the podocyte filtration slits. When the duration of follow-up was increased, necessitating the use of metabolic cages, again, neither proteinuria nor morphological change was induced by the systemic administration of VEGF.
Rats injected with VEGF in the short-term (60-min follow-up) model underwent an acute fall in systemic BP observed immediately upon commencement of the VEGF infusion, with the mean BP two-minutes postcommencement of the infusion being significantly lower than that at commencement of the infusion. An identical effect has previously been reported following the infusion of fibroblast growth factor, which appears to be related to increased nitric oxide (NO) synthesis and resultant vasodilation [35] . In vitro studies on vessels isolated from rabbits have shown that VEGF produces a dose-dependent rise in NO [36] , and the in vivo infusion of VEGF into the coronary circulation has been shown to stimulate NO-dependent dilation of coronary microvessels [37] . Therefore, it appears likely that the observed hemodynamic changes were secondary to NO-mediated vasodilation, and it confirms that the injected rVEGF preparation had significant biological activity at the dose used.
These data refute our hypothesis that high circulating VEGF levels mediate the development of proteinuria in SSNS and that the circulating factor previously detected by others [3] [4] [5] [6] [7] [8] [9] was VEGF.
These rat studies clearly demonstrate that the glomerular capillary endothelium is insensitive to the effects of VEGF circulating in blood. The fact that VEGF was detected at levels in excess of 20 ng/ml at the end of the experiment is important, as it rules out the possibility of neutralization of VEGF by high circulating levels of flt-1 acting as a natural antagonist; the assay does not detect VEGF in the form of such complexes. The glomerular endothelium is reported to express both VEGF receptors, flt-1 and KDR [19] , and ought therefore to be sensitive to the biological action of VEGF similar to other endothelial beds. One potential explanation for the disparity between the results of this study and of those demonstrating increased permeability in other endothelial beds [2, 16] is the direction of presentation of VEGF to the endothelium. We presented VEGF via crete VEGF into the glomerular basement membrane, and in this scenario, glomerular endothelial cells would also naturally encounter VEGF from an abluminal direction. We have previously reported preliminary data suggesting that podocyte VEGF mRNA expression is increased in minimal change disease (abstract; Nephrol Dial Transplant, in press), and this is currently under further investigation. Although these studies have clearly shown that VEGF is not the circulating factor previously described in SSNS, a more indirect role for podocytederived VEGF in the disease pathogenesis cannot be excluded and warrants further study. systemic injection to the luminal endothelial membrane, podocytes, significant producers of VEGF [19] , may se-
